CD274 and non-small cell lung carcinoma: The objective of this investigation was to identify lipid components that may be associated with the therapeutic efficacy of advanced NSCLC treated with a combination of anlotinib and PD-1/PD-L1 inhibitors, from a lipidomics perspective.